May 15, 2022
Video
Dr. Rizzo sits down with HCPLive to discuss the impact of air pollution and allergies on pulmonary health, as well as new research on pulmonary arterial hypertension.
May 14, 2022
President and CEO of SCDAA Regina Hartfield discusses how the association will use the funds from the leadership award.
Dr. Chopra said an FDA-approved treatment for NAFLD could come in the next 6 months.
May 13, 2022
Dr. Gerald Smetana encourages PCPs to familiarize themselves with the outpatient drug options for managing COVID-19 because of the limited treatment window for administration.
Dr. Tara Vijayan talks about how primary care physicians can be best combat misinformation.
Expert psychiatrist Dr. Timothy Fong explains the complexity of using marijuana as treatment in a primary care setting and shares advice on how to address it with patients.
Alcohol use increased during the COVID-19 pandemic, leading to an increase in alcoholic hepatitis.
High-risk individuals should be targeted when drug scarcity comes into play.
May 12, 2022
NAFLD is currently the most prevalent liver disease in the US.
There remains a need to develop more antivirals that can be easily scaled up for COVID-19.
How PREPARE Data, SMART Recommendations Alter Modern Asthma Strategy
Family History of OSA Contributes to Pathogenesis of the Condition
Significant OSA Prevalence in Pediatric Patients with Pulmonary Hypertension